Cowen restated their buy rating on shares of Beigene (NASDAQ:BGNE) in a research report report published on Monday.

BGNE has been the topic of a number of other reports. Goldman Sachs Group reiterated a buy rating and set a $86.00 target price (up from $43.00) on shares of Beigene in a research report on Tuesday, August 15th. Morgan Stanley reiterated an overweight rating and set a $95.00 target price (up from $87.00) on shares of Beigene in a research report on Friday, October 6th. Robert W. Baird restated a neutral rating and issued a $83.00 price objective (up from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Maxim Group restated a buy rating and issued a $120.00 price objective (up from $77.00) on shares of Beigene in a report on Thursday, September 28th. Finally, Zacks Investment Research upgraded shares of Beigene from a hold rating to a buy rating and set a $115.00 price objective on the stock in a report on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Beigene presently has a consensus rating of Buy and a consensus price target of $96.67.

Beigene (NASDAQ:BGNE) opened at $92.99 on Monday. Beigene has a 12-month low of $27.89 and a 12-month high of $118.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33.

Beigene (NASDAQ:BGNE) last announced its earnings results on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million for the quarter, compared to analyst estimates of $1.55 million. During the same quarter in the previous year, the company posted ($1.08) earnings per share. equities analysts forecast that Beigene will post -2.04 earnings per share for the current year.

In other Beigene news, CMO Jane Huang sold 1,600 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $86.25, for a total value of $138,000.00. Following the completion of the sale, the chief marketing officer now owns 264,900 shares of the company’s stock, valued at $22,847,625. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John Oyler sold 150,957 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the sale, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at approximately $39,597,225.50. The disclosure for this sale can be found here. Insiders sold 460,845 shares of company stock worth $39,957,684 over the last 90 days. 19.90% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the business. Hillhouse Capital Management Ltd. increased its stake in Beigene by 172.6% in the second quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after purchasing an additional 2,355,906 shares in the last quarter. Orbimed Advisors LLC increased its position in shares of Beigene by 2.0% during the third quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock worth $135,925,000 after acquiring an additional 26,200 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Beigene during the third quarter worth $62,076,000. Artal Group S.A. increased its position in shares of Beigene by 10.1% during the second quarter. Artal Group S.A. now owns 400,000 shares of the company’s stock worth $18,000,000 after acquiring an additional 36,714 shares in the last quarter. Finally, Myriad Asset Management Ltd. increased its position in shares of Beigene by 16.6% during the second quarter. Myriad Asset Management Ltd. now owns 385,585 shares of the company’s stock worth $17,351,000 after acquiring an additional 54,900 shares in the last quarter. 55.34% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/cowen-reaffirms-buy-rating-for-beigene-bgne/1763216.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.